Inscrição na biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicou 4 edições por ano

ISSN Imprimir: 0893-9675

ISSN On-line: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Tolerance and Cancer: A Critical Issue in Tumor Immunology

Volume 7, Edição 5-6, 1996, pp. 433-456
DOI: 10.1615/CritRevOncog.v7.i5-6.30
Get accessGet access

RESUMO

Self-antigens are the most relevant and abundant antigens to which the host's immune system must be tolerant. Induction and maintenance of tolerance to self-antigens is mediated by several mechanisms that prevent inappropriate damage to normal tissues. However, these same mechanisms may impose potential barriers for the full development of effective immune responses against antigens expressed by tumors. A critical issue in tumor immunology is whether antigen presented by a progressively expanding tumor cell population results in T-cell tolerance. Utilizing a T cell receptor transgenic mice specific for a model tumor antigen expressed on a B-cell lymphoma, recently we have obtained direct evidence supporting the existence of tumor-induced antigen-specific tolerance. A better identification and understanding of the factor(s) involved in tumor-induced tolerance has clear implications for the development of novel cancer immunotherapies aimed at safely breaking tolerance, for example, releasing the brakes on antitumor immune responses while still limiting the induction of undesirable autoimmune responses.

CITADO POR
  1. Spisek Radek, Dhodapkar Madhav V., Immunoprevention of Cancer, Hematology/Oncology Clinics of North America, 20, 3, 2006. Crossref

  2. Jain Ajay, Slansky Jill E., Matey Laurel C., Allen Heather E., Pardoll Drew M., Schulick Richard D., Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor?Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases, Annals of Surgical Oncology, 10, 7, 2003. Crossref

  3. Brentjens Renier J., Sadelain Michel, Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas, in Treatment of Leukemia and Lymphoma, 51, 2004. Crossref

  4. OSTRAND-ROSENBERG SUZANNE, GILBERT MILEKA, CLEMENTS VIRGINIA K., PULASKI BETH A., DISSANAYAKE SAMUDRA, QI LING, Immunologic Targets for the Gene Therapy of Cancer, in Gene Therapy of Cancer, 2002. Crossref

  5. DiSaia Philip J., Tumor Immunology, Host Defense Mechanisms, and Biologic Therapy, in Clinical Gynecologic Oncology, 2007. Crossref

  6. Van Ginderachter Jo A., Liu YuanQing, Geldhof Anja B., Brijs Lea, Thielemans Kris, De Baetselier Patrick, Raes Geert, B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma, International Journal of Cancer, 87, 4, 2000. Crossref

  7. Gitelson Elena, Spaner David, Buckstein Rena, Franssen Edmee, Hewitt Karen, Lim Megan S., Pennell Nancy, Schultze Joachim L., Berinstein Neil L., T-cell analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin, British Journal of Haematology, 116, 1, 2002. Crossref

  8. Ribas Antoni, Ribas-Mundó Manuel, La inmunología antitumoral del 2000 y la nueva terapéutica inmunodepresora, Medicina Clínica, 114, 15, 2000. Crossref

  9. Okazaki Taku, Chikuma Shunsuke, Iwai Yoshiko, Fagarasan Sidonia, Honjo Tasuku, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nature Immunology, 14, 12, 2013. Crossref

  10. Payne Kyle K., Zoon Christine K., Wan Wen, Marlar Khin, Keim Rebecca C., Kenari Mehrab Nasiri, Kazim A. Latif, Bear Harry D., Manjili Masoud H., Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells, Breast Cancer Research and Treatment, 142, 1, 2013. Crossref

  11. Wei Joe, Waithman Jason, Xiao Kun, Oveissi Sara, Chen Weisan, Optimal conditions required for influenza A infection‐enhanced cross‐priming of CD8 + T cells specific to cell‐associated antigens , Immunology & Cell Biology, 91, 9, 2013. Crossref

  12. Albers A. E., Strauss L., Liao T., Hoffmann T. K., Kaufmann A. M., T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer, Clinical and Developmental Immunology, 2010, 2010. Crossref

  13. Ke Yong, Kapp Linda M, Kapp Judith A, Inhibition of tumor rejection by γδ T cells and IL-10, Cellular Immunology, 221, 2, 2003. Crossref

  14. Chen Xiao, Doffek Kara, Sugg Sonia L, Shilyansky Joel, Neuroblastoma cells inhibit the immunostimulatory function of dendritic cells, Journal of Pediatric Surgery, 38, 6, 2003. Crossref

  15. Das Pranab K., van den Wijngaard René M.J.G.J., Wankowicz-Kalinska Anna, Le Poole I.Caroline, A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo, Trends in Immunology, 22, 3, 2001. Crossref

  16. Van Ginderachter Jo A., Movahedi Kiavash, Hassanzadeh Ghassabeh Gholamreza, Meerschaut Sofie, Beschin Alain, Raes Geert, De Baetselier Patrick, Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion, Immunobiology, 211, 6-8, 2006. Crossref

  17. Hess Allan D., Thoburn Christopher J., Miura Yuji, Bright Emilie C., Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen, Clinical Immunology, 114, 3, 2005. Crossref

  18. Nguyen Linh T. , Elford Alisha R. , Murakami Kiichi , Garza Kristine M. , Schoenberger Stephen P. , Odermatt Bernhard , Speiser Daniel E. , Ohashi Pamela S. , Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance , Journal of Experimental Medicine, 195, 4, 2002. Crossref

  19. Schultze Joachim L., Why Do B Cell Lymphoma Fail to Elicit Clinically Sufficient T Cell Immune Responses?, Leukemia & Lymphoma, 32, 3-4, 1999. Crossref

  20. Zhou Gang , Lu Zhengbin , McCadden John D. , Levitsky Hyam I. , Marson Aimee L. , Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression , Journal of Experimental Medicine, 200, 12, 2004. Crossref

  21. Mittelman Abraham, Lucchese Alberta, Sinha Animesh A., Kanduc Darja, Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome, International Journal of Cancer, 98, 5, 2002. Crossref

  22. Maher John, Brentjens Renier J., Gunset Gertrude, Rivière Isabelle, Sadelain Michel, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor, Nature Biotechnology, 20, 1, 2002. Crossref

  23. Waller Edmund K., Ernstoff Marc S., Modulation of antitumor immune responses by hematopoietic cytokines, Cancer, 97, 7, 2003. Crossref

  24. Borrello Ivan, Sotomayor Eduardo M., Rattis Frédérique-Marie, Cooke Sara K., Gu Lingping, Levitsky Hyam I., Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines, Blood, 95, 10, 2000. Crossref

  25. Saudemont Aurore, Quesnel Bruno, In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis, Blood, 104, 7, 2004. Crossref

  26. Heiser Axel, Dahm Philipp, R. Yancey Donna, Maurice Margaret A., Boczkowski David, Nair Smita K., Gilboa Eli, Vieweg Johannes, Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro, The Journal of Immunology, 164, 10, 2000. Crossref

  27. Flynn Sarah, Stockinger Brigitta, Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation, Blood, 101, 11, 2003. Crossref

  28. Dunussi-Joannopoulos Kyriaki, Runyon Kathlene, Erickson Jamie, Schaub Robert G., Hawley Robert G., Leonard John P., Vaccines With Interleukin-12–Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity, Blood, 94, 12, 1999. Crossref

  29. Borrello Ivan, Sotomayor Eduardo M., Rattis Frédérique-Marie, Cooke Sara K., Gu Lingping, Levitsky Hyam I., Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines, Blood, 95, 10, 2000. Crossref

  30. Woods David M., Laino Andressa, Villagra Alejandro, Sotomayor Eduardo M., Molecular Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-specific T-cell Tolerance, in Tumor-Induced Immune Suppression, 2014. Crossref

  31. Dunussi-Joannopoulos Kyriaki, Runyon Kathlene, Erickson Jamie, Schaub Robert G., Hawley Robert G., Leonard John P., Vaccines With Interleukin-12–Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity, Blood, 94, 12, 1999. Crossref

  32. Van Ginderachter Jo, Liu Yuanqing, Devoogdt Nick, Noël Wim, Brys Lea, Gh. Gholamreza Hassanzadeh, Raes Geert, Geldhof Anja, Beschin Alain, Revets Hilde, De Baetselier Patrick, Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion, in Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response, 2008. Crossref

  33. Vicente-Suarez Ildefonso, Villagra Alejandro, Sotomayor Eduardo M., Signaling Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance, in Tumor-Induced Immune Suppression, 2008. Crossref

  34. Wang Hongwei, Cheng Fengdong, Cuenca Alex, Horna Pedro, Zheng Zheng, Bhalla Kapil, Sotomayor Eduardo M., Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance, Blood, 105, 3, 2005. Crossref

  35. Zander Thomas, Re Daniel, von Bergwelt-Baildon Michael, Wolf Jürgen, Schultze Joachim L., Immune Defects in Patients Suffering From Non-Hodgkin’s Lymphoma, in Cancer Immunotherapy at the Crossroads, 2004. Crossref

  36. Moro Kazuki, Nagahashi Masayuki, Gabriel Emmanuel, Takabe Kazuaki, Wakai Toshifumi, Clinical application of ceramide in cancer treatment, Breast Cancer, 26, 4, 2019. Crossref

  37. Liu Yanjun, Peng Yibing, Mi Michael, Guevara-Patino Jose, Munn David H., Fu Ning, He Yukai, Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice, The Journal of Immunology, 182, 10, 2009. Crossref

  38. Zhou Gang, Drake Charles G., Levitsky Hyam I., Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines, Blood, 107, 2, 2006. Crossref

  39. Rabinovich Gabriel A., Gabrilovich Dmitry, Sotomayor Eduardo M., Immunosuppressive Strategies that are Mediated by Tumor Cells, Annual Review of Immunology, 25, 1, 2007. Crossref

  40. Wang Yuanyuan, Gu Tingxuan, Tian Xueli, Li Wenwen, Zhao Ran, Yang Wenqian, Gao Quanli, Li Tiepeng, Shim Jung-Hyun, Zhang Chengjuan, Liu Kangdong, Lee Mee-Hyun, A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy, Frontiers in Immunology, 12, 2021. Crossref

  41. Doan Tracy, Herd Karen, Street Michael, Bryson Gregory, Fernando Germain, Lambert Paul, Tindle Robert, Human Papillomavirus Type 16 E7 Oncoprotein Expressed in Peripheral Epithelium Tolerizes E7-Directed Cytotoxic T-Lymphocyte Precursors Restricted through Human (and Mouse) Major Histocompatibility Complex Class I Alleles, Journal of Virology, 73, 7, 1999. Crossref

  42. el-Shami K, Smith B D, Immunotherapy for myeloid leukemias: current status and future directions, Leukemia, 22, 9, 2008. Crossref

  43. Lin Ken-Yu, Lu Dan, Hung Chien-Fu, Peng Shiwen, Huang Lanqing, Jie Chunfa, Murillo Francisco, Rowley Jesse, Tsai Ya-Chea, He Liangmei, Kim Dae-Jin, Jaffee Elizabeth, Pardoll Drew, Wu T.-C., Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion, Cancer Research, 67, 4, 2007. Crossref

  44. Serafini Paolo, Mgebroff Stephanie, Noonan Kimberly, Borrello Ivan, Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells, Cancer Research, 68, 13, 2008. Crossref

  45. Sotomayor Eduardo M., Borrello Ivan, Tubb Erev, Rattis Frédérique-Marie, Bien Harold, Lu Zhengbin, Fein Steve, Schoenberger Stephen, Levitsky Hyam I., Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40, Nature Medicine, 5, 7, 1999. Crossref

  46. Lustgarten Joseph, Marks James, Sherman Linda A., Redirecting Effector T Cells Through Their IL-2 Receptors, The Journal of Immunology, 162, 1, 1999. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain